Norvir (Ritonavir)

Ritonavir, the active ingredient in Norvir, is a protease inhibitor presented as an oral dosage form for oral use. It is employed in the treatment of HIV infection in both adult and pediatric patients, forming a key component of combination antiretroviral regimens.

GNH USA supplies Norvir as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from consistent product availability and regulatory support.

Ritonavir is used in antiretroviral therapy targeting the HIV protease pathway.

HIV infection: Decreases HIV‑1 viral load by inhibiting protease activity, thereby preventing maturation of viral particles and supporting immune recovery when used as part of combination antiretroviral therapy. HIV‑1 infection (treatment‑experienced): Enhances regimen potency and virologic suppression in patients who have developed resistance to other protease inhibitors.

Ritonavir may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: frequent loose stools. - Vomiting: occasional emesis. - Abdominal pain: cramping or discomfort. - Headache: transient head pain. - Fatigue: feeling unusually tired.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Pancreatitis: inflammation of the pancreas. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - QT interval prolongation: cardiac rhythm disturbances. - Hyperglycemia: increased blood sugar levels. - Lipodystrophy: abnormal fat distribution.

Before initiating ritonavir therapy, clinicians should assess patient-specific risk factors and monitor relevant parameters. - Liver function monitoring: Perform baseline and periodic liver enzyme tests. - Hepatic impairment: Use with caution in patients with moderate to severe liver disease. - Drug‑interaction vigilance: Review concomitant medications for CYP3A4 substrates. - Pregnancy and breastfeeding: Evaluate risk‑benefit ratio; limited data are available. - Store at ambient temperature: Keep below 25°C in the original packaging, protect from moisture and direct sunlight.

Ritonavir is a potent CYP3A4 inhibitor and can alter the exposure of many co‑administered drugs.

Major Interactions (Avoid): - Simvastatin or lovastatin: risk of severe myopathy. - Certain antiarrhythmics (e.g., amiodarone): may cause cardiac toxicity. - Pimozide: increased risk of QT prolongation.

Moderate Interactions (Monitor Closely): - Statins such as atorvastatin: dose adjustment may be required. - Benzodiazepines (e.g., midazolam): enhanced sedation. - Certain antiretrovirals (e.g., efavirenz): may require dose modification.